Depression
The overall baseline PHQ-9 score was 0 to 4 in 3 individuals (5%), 5 to 9 in 9 individuals (15%), 10 to 14 in 15 individuals (24%), 15 to 19 in 21 individuals (34%), and 20 to 27 in 14 individuals (23%). Compared with the control participants, in individuals receiving testosterone, there was a significant decrease in PHQ-9 scores over 3 months’ follow-up (mean difference, −5.6 points; 95% CI, −6.8 to −4.4 points; 